Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.05 (8.333%)
Open: 0.625
High: 0.625
Low: 0.625
Prev. Close: 0.625
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: HSBC Rises After Upbeat Third Quarter

Mon, 29th Oct 2018 10:51

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------HSBC, up 4.7%. The Asia-focused bank reported an "encouraging" third quarter with consensus beating profit. For the three months ended September, pretax profit rose 28% to USD5.92 billion from USD4.62 billion the year prior. Excluding the impact of currency translation, pretax profit rose 16% on the year before. Revenue rose 1.6% to USD13.80 billion from USD13.58 billion the year before. Revenue performance was driven by "strong" growth in all of HSBC's three main global businesses. Shore Capital called HSBC's third-quarter results strong, saying adjusted pretax profit of USD6.19 billion, up 16% on year, was 8% better than consensus at USD5.73 billion and 6% better than Shore's own forecast of USD5.86 billion. Group operating expenses decreased 6.8% to USD7.97 billion from USD8.55 billion the year before. This is largely due the bank's significant items decreasing to USD228 million from USD762 million. The large drop in one-off costs included the non-recurrence of "costs to achieve", which had been USD700 million in the year-ago comparative period. ----------Shire, up 2.5%. Japanese drugmaker Takeda Pharmaceutical said it is considering selling an experimental inflammatory bowel disease drug that is under development by its takeover target Shire. Takeda confirmed its discussion with the European Commission regarding potential overlap between its marketed product Entyvio and Shire's pipeline compound SHP647. SHP647 is a human monoclonal antibody that targets mucosal addressin cell adhesion molecule, which is currently undertaking phase III clinical trials. Takeda has proposed a potential divestment of SHP647 and associated rights. Takeda confirmed on Monday that there are no discussions with the European Commission regarding any other marketed products or assets in the pipeline.----------FTSE 100 - LOSERS----------Just Eat, down 5.2%. Peel Hunt downgraded the online takeaway platform to Sell from Buy. The broker said the rise of rivals Uber and Deliveroo could lead to the demise of Just Eat, given the two can outspend the FTSE 100 constituent and outperform in the smartphone space. Bloomberg in September reported that ride-hailing app Uber - which also offers a food delivery service Uber Eats - was in early discussions with Deliveroo, as part of its strategy to invest and partner with rivals ahead of its planned initial public offering next year.----------OTHER MAIN MARKET AND AIM - WINNERS----------N4 Pharma, up 20%. The cancer-focused pharmaceutical company's shares rose after a key research study demonstrated positive results for its Nuvec delivery system. Since June, N4 Pharma has conducted a research study to determine the level of immune response Nuvec can deliver, using both messenger RNA and plasmid DNA when combined with the antigen Ovalbumin. The results demonstrates that the Nuvec themselves have a clear adjuvant effect to help deliver a level of immune response for both the mRNA and pDNA antigens compared to other delivery systems. As Nuvec will not require an additional adjuvant when formulating a vaccine when used as a delivery system, this could lead to reduced production costs for a final vaccine, as less antigen would be required. In addition, the level of immune response generated by Nuvec particles is within acceptable levels, showing no adverse toxicity.----------Lok'n Store, up 10%. The storage company said its earnings grew in its recently ended financial year following a rise in occupancy and store numbers. Lok'n Store said pretax profit in the year to the end of July improved to GBP5.3 million from GBP4.0 million reported a year earlier, as revenue rose to GBP17.8 million from GBP16.7 million. The company noted the result was driven by occupancy increases in both old and new stores. Tight control over operating costs led to a 2% increase in self-storage margins, which has also contributed in pushing the company's profit to "record level". Lok'nStore declared an annual dividend of 11 pence per share, up 10% from 10p paid the year prior.----------OTHER MAIN MARKET AND AIM - LOSERS----------Warpaint Group, down 43%. The colour cosmetics supplier said the UK market has remained challenging for the company with softening sales, even as it expects a rise in profit and revenue for 2018. Warpaint said its UK market, which accounted for 44% of group's sales in the first half of the year, saw further softening following the end of the interim period due to retailers reducing their stock levels and Christmas orders. The group said the reduction in previously anticipated UK sales will hurt its performance for 2018, which will not be completely offset by an outperformance in its sales territories overseas. As at September 30, sales in the US were up 60% compared to the same period in 2017, and sales in the EU were up 14% year-on-year.----------Gama Aviation, down 17%. The aviation service provider lowered its full-year expectations after trading in some of its divisions has not improved "sufficiently" during the second half of 2018. Gama said it now expects the annual underlying operating profit to be USD3 million below its original expectations. In 2017, Gama generated underlying operating profit of USD18.7 million. On a divisional basis, the company's Air unit saw stable performance in Europe, Middle East & Asia. However, profit from the US is now below Gama's expectations due to slower-than-anticipated growth in charter and aircraft management revenue. In Asia, Gama's associate China Air Services has continued to underperform with the unexpected loss of contracts significantly harming margins. ----------
More News
15 Jul 2022 13:23

N4 Pharma upbeat on latest tumour suppression study data

(Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.

Read more
15 Jul 2022 11:21

AIM WINNERS & LOSERS: Fevertree lowers guidance; DP Poland sales rise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
17 Mar 2022 16:28

UK shareholder meetings calendar - next 7 days

Friday 18 March  
Caracal Gold PLCAGM
Chenavari Toro Income Fund LtdAGM
Monday 21 March 
Aferian PLCAGM
Altona Rare Earths PLCAGM
Helical PLCGM re becoming REIT & buyback
Inland Homes PLCAGM
Tuesday 22 March 
Crest Nicholson Holdings PLCAGM
Hochschild Mining PLCEGM re Amarillo Gold acquisition
Hydro Hotel Eastbourne PLCAGM
Starvest PLCAGM
Sureserve Group plcAGM
Wynnstay Group PLCAGM
Wednesday 23 March 
CML Microsystems PLCGM re employee share plans
Quartix Technologies PLCAGM
Strategic Equity Capital PLCGM re: tender offer
Thursday 24 March 
BlackRock Throgmorton Trust PLCAGM
Independent Investment Trust PLCAGM
N4 Pharma PLCAGM
React Group PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
23 Feb 2022 14:54

IN BRIEF: N4 Pharma falls as loss widens and Nuvec tests inconclusive

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Reports a pretax loss of GBP1.8 million for 2021, widening 18% from GBP1.6 million the previous year. Says year focused on in vivo studies of Nuvec, a delivery system for cancer treatments and vaccines, which did not return any "meaningful" immunological response in studies carried out by Hamburg-based drug development company Evotec SE. Says that on the back of increased data the company can now narrow its focus on the oncology and gene therapy market.

Read more
31 Jan 2022 22:06

TRADING UPDATES: Hiro plans acquisition vehicle IPO; Aquila reviews

TRADING UPDATES: Hiro plans acquisition vehicle IPO; Aquila reviews

Read more
25 Jan 2022 19:12

TRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends

TRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends

Read more
25 Jan 2022 14:50

N4 Pharma outlines work plan after 'encouraging' data

(Sharecast News) - Specialist treatment and vaccine delivery system developer N4 Pharma updated the market on its work plan on Tuesday, following "encouraging data" from its oncology research as announced on 13 December.

Read more
13 Dec 2021 21:57

IN BRIEF: N4 Pharma to focus resources on gene therapy

IN BRIEF: N4 Pharma to focus resources on gene therapy

Read more
13 Dec 2021 14:56

N4 upbeat on cancer treatment progress, vaccine disappoints

(Sharecast News) - Cancer treatment and vaccine delivery system developer N4 Pharma updated the market on data from its proof-of-concept programmes and ongoing activities on Monday.

Read more
1 Nov 2021 06:57

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

Read more
1 Oct 2021 09:35

N4 Pharma granted Europe patent with China equivalent on its way

(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced on Friday that it has been granted a patent for its 'Nuvec' cancer treatment and vaccine delivery system by the European Patent Office (EPO), specifically around its composition, particulate materials, and methods for making the particulate materials.

Read more
1 Oct 2021 08:50

N4 Pharma secures patent in Europe for Nuvec, expects China to follow

N4 Pharma secures patent in Europe for Nuvec, expects China to follow

Read more
20 Sep 2021 12:02

TRADING UPDATES: Christie Group and Open Orphan swing to profit

TRADING UPDATES: Christie Group and Open Orphan swing to profit

Read more
14 Sep 2021 14:31

TRADING UPDATES: Boku launches in Germany; Focusrite trading well

TRADING UPDATES: Boku launches in Germany; Focusrite trading well

Read more
24 Aug 2021 12:35

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.